Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In one of them, SCORAD was not compared directly between groups, and the product also contained gamma-linolenic acid and vitamin D₃ (9).
Source: Narrative synthesis of findings. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Prenatal and postnatal omega-3 supplementation for the prevention and treatment of atopic dermatitis: a systematic review of randomized controlled trials
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Full studies
Prenatal and postnatal omega-3 supplementation for the prevention and treatment of atopic dermatitis: a systematic review of randomized controlled trials
Systematic review · Frontiers in Allergy · 2026
Original publication title
Prenatal and postnatal omega-3 supplementation for the prevention and treatment of atopic dermatitis: a systematic review of randomized controlled trials
© 2026 Aljabri, Alzahrani, Sulaymani, Sulaimani, Alzahrani and Nahhas.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To systematically review and narratively synthesize randomized controlled trial evidence on prenatal and postnatal omega-3 fatty acid supplementation for the prevention and treatment of AD in infants and children.
Source: ObjectiveStudy methods
What methods does the paper describe?
Study design
This study was conducted as a systematic review of randomized controlled trials (RCTs) evaluating the effects of prenatal and postnatal omega-3 (n-3 long-chain polyunsaturated fatty acid) supplementation for the prevention and treatment of atopic dermatitis (AD) and related allergic outcomes in children.
Reporting standards
This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The study selection process, including identification, screening, eligibility, and inclusion of studies, is presented in a PRISMA flow diagram (Figure 1).
PRISMA 2020 flow diagram of study selection.
Protocol registration
The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420251161453). Although the protocol initially allowed inclusion of multiple study designs, only randomized controlled trials met the eligibility criteria following full-text screening.
Eligibility criteria
Types of studies
Only randomized controlled trials were included. Observational studies, animal studies, reviews, editorials, conference abstracts, and nonrandomized trials were excluded.
Types of participants
Eligible participants included pregnant women (prenatal supplementation trials) and pediatric populations (infants or children). Studies evaluating either prevention of atopic dermatitis or treatment of established atopic dermatitis were eligible.
Types of interventions
The intervention of interest was omega-3 fatty acid supplementation, including formulations containing docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or combined omega-3 preparations. Supplementation administered prenatally, postnatally, or both was eligible. Trials using multi-component supplements were eligible if omega-3 fatty acids were a main component; these were identified and interpreted separately, as effects could not be attributed to omega-3 alone.
Outcomes
Studies were included if they reported at least one atopic dermatitis outcome, including incidence or prevalence of AD (eczema), severity of AD assessed using validated tools (e.g., SCORAD), or use of topical corticosteroids. Other allergic outcomes were extracted where reported.
Information sources
A systematic literature search was conducted in October 2025 using the following electronic databases: PubMed and Web of Science. Additional records were identified through supplementary searching of Google Scholar and reference lists of included studies. The search was updated on 2 October 2026 in PubMed, as Web of Science and Embase were not accessible through our institution at the time of the update. Reference lists of included trials were also checked to identify additional eligible studies.
Search strategy
A structured search strategy was developed using relevant keywords and medical subject headings related to omega-3 fatty acids, atopic dermatitis, eczema, pregnancy, infants, and randomized controlled trials. All retrieved records were imported into Rayyan systematic review software for duplicate removal and screening. Records from the updated search were added to the same Rayyan project, and duplicates of previously screened records were removed. The full search strategy for the updated search is provided in Supplementary Table S1.
Study selection
Study selection was performed using Rayyan. Four reviewers independently screened studies in two stages: title and abstract screening, followed by full-text review for eligibility when necessary. Any disagreements regarding study inclusion were resolved through discussion or consultation with a senior reviewer. The same process was applied to records identified in the updated search. Reports excluded at eligibility assessment, with reasons, are listed in Supplementary Table S2.
Data extraction
Data were extracted using a predefined data extraction form. Extracted information included author and year of publication, study population, timing of omega-3 supplementation (prenatal or postnatal), clinical indication (prevention or treatment), omega-3 formulation, dosage and duration, comparator, outcomes assessed, event counts and effect estimates with 95% confidence intervals where available, and length of follow-up. Data were extracted by one reviewer and checked against the original reports by a second reviewer. When multiple publications reported results from the same trial, they were treated as a single study.
Data from all reports were extracted and organized at the trial level, including longer-term follow-up outcomes where available. A summary of study characteristics and outcomes is presented in Table 1, with the complete data extraction table provided in Supplementary Table S3.
Characteristics of included randomized controlled trials evaluating omega-3 supplementation and atopic dermatitis.
| Study (Year) | Populations | N randomized/analysed | Intervention (Daily dose; Timing) | Comparator | AD outcome; follow-up | Main AD result (intervention vs. control; 95% CI) |
|---|---|---|---|---|---|---|
| Prevention: Prenatal Supplementation | ||||||
| Dunstan et al. (14) (2003) | Pregnant atopic women | 98/ 83a | 4 × 1 g fish oil capsules/day = 3.7 g n-3 PUFA/day (56.0% DHA, 27.7% EPA); 20 weeks' gestation to delivery | 4 × 1 g olive oil capsules/day | physician-diagnosed eczema responsive to topical steroids. Severity: modified SCORAD, (12 months) | AD: 18/40 vs. 13/43; OR 1.88 (0.77 to 4.65). Severe AD among infants with AD: 1/18 vs. 5/13; OR 0.09 (0.01 to 0.94) |
| Furuhjelm et al. (15, 18) (2009) | Pregnant women with family history of allergy | 145/117a | Nine 500 mg capsules/day (Bio Marin, Pharma Nord): 1.6 g EPA (35%) + 1.1 g DHA (25%) + 23 mg alpha-tocopherol per day; 25th gestational week to average 3-4 months of breastfeeding | nine soy oil capsules/day | IgE-associated eczema,(1 and 2 years) | 1 year: 4/52 vs. 15/63; adjusted OR 0.22 (0.06 to 0.81). 2 years (cumulative): 5/54 vs. 15/63; adjusted OR 0.33 (0.10 to 1.10) |
| Palmer et al. (13, 19, 20) (2012) | Infants at high hereditary risk: mother, father or sibling with medically diagnosed allergic disease | 706/706b | 3 × 500 mg DHA-rich fish oil concentrate capsules daily (800 mg DHA + 100 mg EPA; 900 mg n-3 LCPUFA/day); 21 weeks' gestation to delivery. | 3 × 500 mg vegetable oil capsules daily | IgE-associated eczema,(1,3,6 years) | 1 year: 26/368 vs. 39/338; unadjusted RR 0.61 (0.38 to 0.98); adjusted RR 0.64 (0.40 to 1.03). 3 years: 13.8% vs. 19.0%; adjusted RR 0.75 (0.53 to 1.05). 6 years (IgE-associated allergic disease): 31.5% vs. 31.5%; adjusted RR 1.04 (0.82 to 1.33) |
| Berman et al. (16) (2016) | Pregnant women with past depression | 126/ 84c | EPA-rich fish oil 1060 mg EPA + 274 mg DHA; DHA-rich fish oil 900 mg DHA + 180 mg EPA. Once daily; Started at 12-20 weeks' gestation | Soy oil | Mother-reported by phone, No clinical examination or allergy testing, (36 months) | EPA 13/31 and DHA 10/26 vs. placebo 3/27; adjusted OR 8.1 (1.4 to 46.3) for EPA and 9.5 (1.5 to 59.6) for DHA |
| Komulainen et al. (12) (2023) | Women with self-reported prepregnancy BMI ≥25 kg/m2, under 18 gestational weeks, without chronic disease (allergic disease allowed) | 439/264d | Fish oil 2 capsules/day = 2.4 g n-3 (1.9 g DHA, 0.22 g EPA; Croda); 14 ± 2 gestational weeks to 6 months postpartume | medium-chain fatty acids | Atopic eczema diagnosed by the child's personal physician, (12 and 24 months) | 24 months: 11/68 vs. 11/66e; fish oil main effect adjusted OR 1.22 (0.64 to 2.33) |
| Chen et al. (7) (2024) | Pregnant women not selected for allergy risk | 736/635 | 2.4 g/d of n-3 LCPUFA (55% EPA and 37% DHA) Once Daily; 24 weeks' gestation to 1 week postpartum | olive oil | Childhood AD diagnosis clinic by Hanifin and Rajka criteria, until age 10 years | No overall effect: HR 1.00 (0.76 to 1.33). Effect modified by maternal PTGS1 genotype (interaction P < 0.001)f |
| Prevention: Postnatal Supplementation | ||||||
| Marks et al. (11) (2006) | Pregnant women whose unborn child had an increased risk of asthma | 616/516 | 500mg of daily tuna fish oil (∼184 mg omega-3); started by bottle-feeding or solids by 6 months to 5 yearse,g | Sunola oil capsules | Current eczema inspection by the assessment nurse OR parent-reported itchy rash; 5 years | 54/267 vs. 59/249; RR 0.85 (0.61 to 1.17) |
| Gunaratne et al. (10) (2019) | Preterm infants <33 wk gestation | 657/569 | Breast-feeding mothers: six 0.5 g DHA-rich fish oil capsules/day (900 mg DHA + 195 mg EPA) to raise breast milk DHA to ∼1% of total fatty acids. Infants needing formula: high-DHA preterm formula (∼1.0% DHA, ∼0.6% AA). 2-4 d of postnatal age to 40 wk postmenstrual age | Standard-DHA feedsh | parent-reported via ISAAC questionnaire; 18 months and 7 years | Previous 12 months: 36/278 vs. 28/291; adjusted RR 1.38 (0.86 to 2.21). Birth to 7 years: 43/278 vs. 43/291; adjusted RR 1.08 (0.72 to 1.62) |
| D'Vaz et al. (17) (2012) | Healthy term infants of allergic women | 420/ 323 | Fish oil capsule 650 mg daily providing 280 mg DHA + 110 mg EPA; From Birth to 6 months of age | Olive oil capsule 650 mg daily | Physician-diagnosed eczema (Hanifin: Rajka criteria); 6 and 12 months | 61/156 vs. 68/167; no significant difference (effect estimate not reported) |
| Treatment | ||||||
| Mirrahimi et al. (8) (2023) | Children aged 3 months to 18 years with AD | 48/43a | PA softgels 250 mg twice daily (500 mg/day) for 4 weeks | Placebo softgels | SCORAD (online calculator) at baseline; 2 and 4 weeks | SCORAD at 4 weeks: 18.01 ± 10.63 vs. 30.11 ± 9.58 (P = 0.001)a. Topical corticosteroids needed: 7/21 vs. 14/22 (P = 0.047) |
| Niseteo et al. (9) (2024) | Children aged 1 to 8 years with AD and SCORAD >25 (moderate to severe) | 53/52 | 600 mg EPA + 400 mg DHA with GLA 10 mg and vitamin D₃ 5 mcg; 4 monthsg | 5 mL once daily: MCT oil | SCORAD, PO-SCORAD and TCS use; 4 months | Median SCORAD, within group: 42 to 25 (P < 0.001) vs. 39 to 39 (P = 0.795); no between-group SCORAD comparison. PO-SCORAD change: 13 vs. −1 (P < 0.001) |
Results are intervention vs. control. Doses are per day. Effect estimates are as reported by each trial.
Per-protocol analysis. bAll randomized infants analysed using multiple imputation. c126 women randomized in the original trial, 118 completed; 84 children analysed (secondary, unplanned analysis). dChildren analysed at 24 months. eFactorial design: Komulainen 2023 with probiotics (counts shown for fish oil + placebo vs. placebo + placebo; odds ratio is the fish oil main effect, interaction P = 0.593); Marks 2006 with house dust mite avoidance (diet groups shown). fPrespecified secondary analysis. gMulti-component intervention; effects cannot be attributed to omega-3 alone. hActive comparator, not placebo.
AA, arachidonic acid; AD, atopic dermatitis; BMI, body mass index; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; HR, hazard ratio; ISAAC, International Study of Asthma and Allergies in Childhood; LCPUFA, long-chain polyunsaturated fatty acids; MCT, medium-chain triglycerides; OR, odds ratio; PO-SCORAD, patient-oriented SCORAD; PUFA, polyunsaturated fatty acids; RR, relative risk; SCORAD, scoring atopic dermatitis; TCS, topical corticosteroids.
Risk of bias assessment
The methodological quality of included studies was assessed using the Cochrane Risk of Bias tool version 2 (RoB 2). Five domains were evaluated: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of outcomes, and bias in selection of the reported result. Each domain was rated as low risk of bias, some concerns, or high risk of bias, and an overall risk of bias judgment was assigned in accordance with Cochrane guidance.
Risk of bias was assessed for the main AD outcome of each trial, and a justification was recorded for each domain (Supplementary Table S4). Results were summarized using a traffic-light plot (Figure 2).
Risk of bias assessment of included trials using the cochrane roB 2 tool. D1, randomization process; D2, deviations from intended interventions; D3, missing outcome data; D4, measurement of the outcome; D5, selection of the reported result. Green, low risk of bias; yellow, some concerns; red, high risk of bias. Overall risk of bias was low for one trial, some concerns for seven trials and high for three trials.
Data synthesis
Because included trials differed in clinical indication, studies were grouped first by indication (primary prevention of AD vs. treatment of established AD) and then by timing of supplementation (prenatal vs. postnatal). Direct comparison of prenatal and postnatal supplementation was considered only within the prevention category. A meta-analysis was not performed because trials differed substantially in supplementation dose and formulation, timing of initiation, definition of AD outcomes (e.g., any eczema vs. IgE-associated eczema), and length of follow-up. Instead, a structured narrative synthesis was conducted, considering methodological quality and risk of bias.
Trial-level effect estimates with 95% confidence intervals are reported in Table 1 where available.
Results: Study selection
The searches identified 614 records (PubMed, n = 292; Web of Science, n = 117; Google Scholar, n = 205), including the original search and the updated PubMed search. After removal of 192 duplicates, 422 records were screened by title and abstract, of which 395 were excluded. Of the 27 reports sought for retrieval, 6 could not be retrieved, and 21 were assessed for eligibility. Six reports were excluded, with reasons listed in Supplementary Table S2. In total, 11 randomized controlled trials, reported in 15 publications, were included (Figure 1).
Six trials were identified in the original search, and five additional trials were identified in the updated search.
Source: Study selectionResults: Study characteristics
The included trials were published between 2003 and 2024 and varied widely in sample size (48 to 736 participants), intervention timing, omega-3 formulation, dosage, and duration of follow-up (4 weeks to 10 years). Study populations included pregnant women with or without a personal history of allergic disease, preterm and term infants at varying baseline risks for atopy, and pediatric patients with established atopic dermatitis. Omega-3 interventions consisted of EPA-rich, DHA-rich, and mixed LCPUFA formulations administered at various daily dosages, compared against controls including soy oil, olive oil, vegetable oil, omega-6-rich oils, medium-chain triglycerides, or paraffin; one trial compared high-DHA with standard-DHA feeds rather than placebo (10).
Two trials used multi-component interventions, combining omega-3 with gamma-linolenic acid and vitamin D₃ (9) or with omega-6 restriction (11), and two had factorial designs (11, 12). Atopic dermatitis outcomes were defined as physician-diagnosed eczema, IgE-associated eczema, parent-reported or nurse-assessed eczema, or SCORAD. Study characteristics are summarized in Table 1.
Characteristics of included randomized controlled trials evaluating omega-3 supplementation and atopic dermatitis.
| Study (Year) | Populations | N randomized/analysed | Intervention (Daily dose; Timing) | Comparator | AD outcome; follow-up | Main AD result (intervention vs. control; 95% CI) |
|---|---|---|---|---|---|---|
| Prevention: Prenatal Supplementation | ||||||
| Dunstan et al. (14) (2003) | Pregnant atopic women | 98/ 83a | 4 × 1 g fish oil capsules/day = 3.7 g n-3 PUFA/day (56.0% DHA, 27.7% EPA); 20 weeks' gestation to delivery | 4 × 1 g olive oil capsules/day | physician-diagnosed eczema responsive to topical steroids. Severity: modified SCORAD, (12 months) | AD: 18/40 vs. 13/43; OR 1.88 (0.77 to 4.65). Severe AD among infants with AD: 1/18 vs. 5/13; OR 0.09 (0.01 to 0.94) |
| Furuhjelm et al. (15, 18) (2009) | Pregnant women with family history of allergy | 145/117a | Nine 500 mg capsules/day (Bio Marin, Pharma Nord): 1.6 g EPA (35%) + 1.1 g DHA (25%) + 23 mg alpha-tocopherol per day; 25th gestational week to average 3-4 months of breastfeeding | nine soy oil capsules/day | IgE-associated eczema,(1 and 2 years) | 1 year: 4/52 vs. 15/63; adjusted OR 0.22 (0.06 to 0.81). 2 years (cumulative): 5/54 vs. 15/63; adjusted OR 0.33 (0.10 to 1.10) |
| Palmer et al. (13, 19, 20) (2012) | Infants at high hereditary risk: mother, father or sibling with medically diagnosed allergic disease | 706/706b | 3 × 500 mg DHA-rich fish oil concentrate capsules daily (800 mg DHA + 100 mg EPA; 900 mg n-3 LCPUFA/day); 21 weeks' gestation to delivery. | 3 × 500 mg vegetable oil capsules daily | IgE-associated eczema,(1,3,6 years) | 1 year: 26/368 vs. 39/338; unadjusted RR 0.61 (0.38 to 0.98); adjusted RR 0.64 (0.40 to 1.03). 3 years: 13.8% vs. 19.0%; adjusted RR 0.75 (0.53 to 1.05). 6 years (IgE-associated allergic disease): 31.5% vs. 31.5%; adjusted RR 1.04 (0.82 to 1.33) |
| Berman et al. (16) (2016) | Pregnant women with past depression | 126/ 84c | EPA-rich fish oil 1060 mg EPA + 274 mg DHA; DHA-rich fish oil 900 mg DHA + 180 mg EPA. Once daily; Started at 12-20 weeks' gestation | Soy oil | Mother-reported by phone, No clinical examination or allergy testing, (36 months) | EPA 13/31 and DHA 10/26 vs. placebo 3/27; adjusted OR 8.1 (1.4 to 46.3) for EPA and 9.5 (1.5 to 59.6) for DHA |
| Komulainen et al. (12) (2023) | Women with self-reported prepregnancy BMI ≥25 kg/m2, under 18 gestational weeks, without chronic disease (allergic disease allowed) | 439/264d | Fish oil 2 capsules/day = 2.4 g n-3 (1.9 g DHA, 0.22 g EPA; Croda); 14 ± 2 gestational weeks to 6 months postpartume | medium-chain fatty acids | Atopic eczema diagnosed by the child's personal physician, (12 and 24 months) | 24 months: 11/68 vs. 11/66e; fish oil main effect adjusted OR 1.22 (0.64 to 2.33) |
| Chen et al. (7) (2024) | Pregnant women not selected for allergy risk | 736/635 | 2.4 g/d of n-3 LCPUFA (55% EPA and 37% DHA) Once Daily; 24 weeks' gestation to 1 week postpartum | olive oil | Childhood AD diagnosis clinic by Hanifin and Rajka criteria, until age 10 years | No overall effect: HR 1.00 (0.76 to 1.33). Effect modified by maternal PTGS1 genotype (interaction P < 0.001)f |
| Prevention: Postnatal Supplementation | ||||||
| Marks et al. (11) (2006) | Pregnant women whose unborn child had an increased risk of asthma | 616/516 | 500mg of daily tuna fish oil (∼184 mg omega-3); started by bottle-feeding or solids by 6 months to 5 yearse,g | Sunola oil capsules | Current eczema inspection by the assessment nurse OR parent-reported itchy rash; 5 years | 54/267 vs. 59/249; RR 0.85 (0.61 to 1.17) |
| Gunaratne et al. (10) (2019) | Preterm infants <33 wk gestation | 657/569 | Breast-feeding mothers: six 0.5 g DHA-rich fish oil capsules/day (900 mg DHA + 195 mg EPA) to raise breast milk DHA to ∼1% of total fatty acids. Infants needing formula: high-DHA preterm formula (∼1.0% DHA, ∼0.6% AA). 2-4 d of postnatal age to 40 wk postmenstrual age | Standard-DHA feedsh | parent-reported via ISAAC questionnaire; 18 months and 7 years | Previous 12 months: 36/278 vs. 28/291; adjusted RR 1.38 (0.86 to 2.21). Birth to 7 years: 43/278 vs. 43/291; adjusted RR 1.08 (0.72 to 1.62) |
| D'Vaz et al. (17) (2012) | Healthy term infants of allergic women | 420/ 323 | Fish oil capsule 650 mg daily providing 280 mg DHA + 110 mg EPA; From Birth to 6 months of age | Olive oil capsule 650 mg daily | Physician-diagnosed eczema (Hanifin: Rajka criteria); 6 and 12 months | 61/156 vs. 68/167; no significant difference (effect estimate not reported) |
| Treatment | ||||||
| Mirrahimi et al. (8) (2023) | Children aged 3 months to 18 years with AD | 48/43a | PA softgels 250 mg twice daily (500 mg/day) for 4 weeks | Placebo softgels | SCORAD (online calculator) at baseline; 2 and 4 weeks | SCORAD at 4 weeks: 18.01 ± 10.63 vs. 30.11 ± 9.58 (P = 0.001)a. Topical corticosteroids needed: 7/21 vs. 14/22 (P = 0.047) |
| Niseteo et al. (9) (2024) | Children aged 1 to 8 years with AD and SCORAD >25 (moderate to severe) | 53/52 | 600 mg EPA + 400 mg DHA with GLA 10 mg and vitamin D₃ 5 mcg; 4 monthsg | 5 mL once daily: MCT oil | SCORAD, PO-SCORAD and TCS use; 4 months | Median SCORAD, within group: 42 to 25 (P < 0.001) vs. 39 to 39 (P = 0.795); no between-group SCORAD comparison. PO-SCORAD change: 13 vs. −1 (P < 0.001) |
Results are intervention vs. control. Doses are per day. Effect estimates are as reported by each trial.
Per-protocol analysis. bAll randomized infants analysed using multiple imputation. c126 women randomized in the original trial, 118 completed; 84 children analysed (secondary, unplanned analysis). dChildren analysed at 24 months. eFactorial design: Komulainen 2023 with probiotics (counts shown for fish oil + placebo vs. placebo + placebo; odds ratio is the fish oil main effect, interaction P = 0.593); Marks 2006 with house dust mite avoidance (diet groups shown). fPrespecified secondary analysis. gMulti-component intervention; effects cannot be attributed to omega-3 alone. hActive comparator, not placebo.
AA, arachidonic acid; AD, atopic dermatitis; BMI, body mass index; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; HR, hazard ratio; ISAAC, International Study of Asthma and Allergies in Childhood; LCPUFA, long-chain polyunsaturated fatty acids; MCT, medium-chain triglycerides; OR, odds ratio; PO-SCORAD, patient-oriented SCORAD; PUFA, polyunsaturated fatty acids; RR, relative risk; SCORAD, scoring atopic dermatitis; TCS, topical corticosteroids.
Results: Quality assessment
Risk of bias was assessed using RoB 2 for the main AD outcome of each trial (Figure 2; Supplementary Table S4). Overall risk of bias was low for one trial (13), some concerns for seven trials (7Not reported11, 14, 15), and high for three trials (12, 16, 17). All three high-risk judgments were due to missing outcome data: 84 of 126 randomized women were included in one trial (16), 264 of 439 randomized participants contributed 24-month data in another (12), and 323 of 420 randomized infants were assessed at 12 months, with greater loss from the fish oil group, in the third (17).
Some concerns most often arose from missing outcome data and from the lack of an accessible prespecified analysis plan for the specific result. Outcome measurement raised concerns where eczema was based on parent or maternal report, or where blinding was not maintained throughout follow-up (7, 11, 12, 16). Two trials did not describe sequence generation and allocation concealment in sufficient detail (11, 15).
Source: Quality assessmentResults of individual studies
Prevention of atopic dermatitis
Nine trials evaluated omega-3 supplementation for the primary prevention of AD: six prenatal (7, 12Not reported16) and three postnatal (10, 11, 17).
Prenatal supplementation
Dunstan et al. (2003) conducted a randomized controlled trial involving 98 atopic pregnant women (14). Participants received fish oil providing 3.7 g n-3 PUFA daily (56% DHA, 27.7% EPA) or olive oil from 20 weeks' gestation until delivery, and 83 infants were analyzed per protocol. The frequency of AD at 12 months did not differ between groups (18/40 vs. 13/43; OR 1.88, 95% CI 0.77 to 4.65). However, among infants who developed AD, severe disease was less common in the fish oil group (1/18 vs. 5/13; OR 0.09, 95% CI 0.01 to 0.94), although this subgroup was small.
Furuhjelm et al. (2009) conducted a randomized controlled trial involving 145 pregnant women with a family history of allergy (15). Participants received 1.6 g EPA and 1.1 g DHA daily or soy oil from 25 weeks' gestation through an average of 3 to 4 months of breastfeeding. In the per-protocol analysis of 117 children, IgE-associated eczema at 1 year was lower in the omega-3 group (4/52, 8% vs. 15/63, 24%; adjusted OR 0.22, 95% CI 0.06 to 0.81). At 2 years, the cumulative incidence of IgE-associated eczema remained lower but was no longer significant after adjustment (adjusted OR 0.33, 95% CI 0.10 to 1.10), and any eczema did not differ between groups (18).
Twenty-five women who did not complete supplementation were excluded from the main analysis, more of them in the omega-3 group, and the intention-to-treat analysis showed only a trend.
Palmer et al. (2012) conducted a randomized controlled trial involving 706 infants at high hereditary risk within the DOMInO trial (13). Mothers received 900 mg n-3 LCPUFA daily (800 mg DHA and 100 mg EPA) or vegetable oil from 21 weeks' gestation until delivery. The primary outcome, IgE-associated allergic disease at 1 year, was not reduced (adjusted RR 0.70, 95% CI 0.45 to 1.09). IgE-associated eczema was less frequent in the omega-3 group (26/368, 7% vs. 39/338, 12%; unadjusted RR 0.61, 95% CI 0.38 to 0.98), but this was not significant after adjustment (adjusted RR 0.64, 95% CI 0.40 to 1.03).
At 3 years, IgE-associated eczema remained lower but not significantly (13.8% vs. 19.0%; adjusted RR 0.75, 95% CI 0.53 to 1.05) (19). At 6 years, IgE-associated allergic disease did not differ between groups (31.5% vs. 31.5%; adjusted RR 1.04, 95% CI 0.82 to 1.33) (20).
Berman et al. (2016) reported a secondary, unplanned analysis of a randomized controlled trial in pregnant women at risk of depression (16). Participants received EPA-rich fish oil (1060 mg EPA and 274 mg DHA), DHA-rich fish oil (900 mg DHA and 180 mg EPA) or soy oil from 12 to 20 weeks' gestation. In 84 of 118 completers, mother-reported eczema at 36 months was more frequent in both omega-3 groups than with placebo (EPA 13/31, 41.9%; DHA 10/26, 38.5%; placebo 3/27, 11.1%).
The adjusted odds ratios were 8.1 (95% CI 1.4 to 46.3) for EPA and 9.5 (95% CI 1.5 to 59.6) for DHA.
Komulainen et al. (2023) conducted a factorial randomized controlled trial involving 439 overweight pregnant women (12). Participants received fish oil (1.9 g DHA and 0.22 g EPA daily) and/or probiotics, or placebo, from about 14 weeks' gestation until 6 months postpartum. Fish oil had no effect on physician-diagnosed atopic eczema at 12 or 24 months. At 24 months, atopic eczema occurred in 11/68 (16%) children in the fish oil plus placebo group and 11/66 (17%) in the placebo-only group.
Chen et al. (2024) reported a prespecified secondary analysis of the COPSAC2010 trial, which included 736 pregnant women from an unselected cohort (7). Participants received 2.4 g n-3 LCPUFA daily (55% EPA and 37% DHA) or olive oil from 24 weeks' gestation until 1 week postpartum. There was no overall effect on AD up to 10 years of age (HR 1.00, 95% CI 0.76 to 1.33). However, the effect differed by maternal PTGS1 (COX-1) genotype (interaction P < 0.001). AD risk was lower among offspring of mothers with the TT genotype, unchanged with CT, and higher with CC.
Overall, prenatal omega-3 supplementation did not show a consistent preventive effect on AD. Reductions were mainly seen for IgE-associated eczema in high-risk families, were not always significant after adjustment, and did not persist at longer follow-up.
Postnatal supplementation
Marks et al. (2006) conducted a factorial randomized controlled trial involving 616 infants at high risk of asthma, which also tested house dust mite avoidance (11). The active diet group received tuna oil capsules with canola-based oils and spreads, and the control group received omega-6-rich oils and spreads with Sunola oil capsules, from the start of bottle-feeding or 6 months of age until 5 years. Among 516 children assessed at 5 years, current eczema did not differ between the active and control diet groups (54/267 vs. 59/249; RR 0.85, 95% CI 0.61 to 1.17).
Because the active diet also restricted omega-6 fatty acids, this effect cannot be attributed to omega-3 alone.
The DINO trial randomized 657 infants born before 33 weeks' gestation to high-DHA (about 1% of total fatty acids) or standard-DHA (about 0.3%) enteral feeds (10). The feeds were given through maternal fish oil capsules or preterm formula, from 2 to 4 days of age until 40 weeks' postmenstrual age. At 7 years, data were available for 569 children (87%). Parent-reported eczema in the previous 12 months did not differ between groups (13.0% vs. 9.6%; adjusted RR 1.38, 95% CI 0.86 to 2.21), and neither did eczema from birth to 7 years (15.5% vs. 14.8%; adjusted RR 1.08, 95% CI 0.72 to 1.62).
D'Vaz et al. (2012) conducted a randomized controlled trial involving 420 high-risk infants (17). Infants received fish oil (280 mg DHA and 110 mg EPA daily) or olive oil placebo from birth to 6 months, with clinical follow-up at 12 months (n = 323). This study found no significant difference in physician-diagnosed eczema between groups (61/156, 39.1% vs. 68/167, 40.7%), or in any other allergic outcome. Higher infant n-3 PUFA levels at 6 months were associated with lower eczema risk, but this association was not significant after correction for multiple comparisons or adjustment for group allocation.
Withdrawal was higher in the fish oil group (18.3% vs. 10.9%), and most fish oil participants correctly guessed their allocation.
Overall, none of the three postnatal prevention trials found a significant effect on AD.
Treatment of established atopic dermatitis
Two trials evaluated omega-3 supplementation in children with established AD, both postnatal by design (8, 9).
Mirrahimi et al. (2023) conducted a triple-blind randomized controlled trial involving 48 children aged 3 months to 18 years with AD (8). Participants received EPA 250 mg twice daily (500 mg/day) or placebo for 4 weeks, and both groups also used an emollient and 1% hydrocortisone ointment. Baseline SCORAD was similar between groups (49.65 ± 8.29 vs. 46.91 ± 11.37). SCORAD was lower in the EPA group at 2 weeks (30.50 ± 8.92 vs. 38.34 ± 10.52, P = 0.005) and at 4 weeks in the per-protocol analysis (18.01 ± 10.63 vs. 30.11 ± 9.58, P = 0.001).
Fewer children in the EPA group needed topical corticosteroids at 4 weeks (7/21, 33.3% vs. 14/22, 63.6%, P = 0.047). Confidence intervals were not reported.
Niseteo et al. (2024) conducted a triple-blind randomized controlled trial involving 53 children aged 1 to 8 years with moderate-to-severe AD (9). Participants received a daily syrup providing 600 mg EPA and 400 mg DHA, together with gamma-linolenic acid (10 mg) and vitamin D₃ (5 mcg), or placebo for 4 months, and 52 children were analyzed. Both groups also used emollients and low-potency topical corticosteroids. Median SCORAD decreased from 42 to 25 in the intervention group (P < 0.001) and did not change in the placebo group (39 to 39, P = 0.795), but SCORAD was not compared directly between groups.
Between-group comparisons showed greater improvement with the intervention in patient-oriented SCORAD (median change 13 vs. −1, P < 0.001), itch (3 vs. 0, P < 0.001), sleep disturbance (3 vs. 0, P = 0.001) and family quality of life (5 vs. 0, P < 0.001). Parent-reported topical corticosteroid use fell from 30 to 10 mg/month in the intervention group (P < 0.001) and rose from 30 to 50 mg/month in the placebo group (P = 0.031). Because the active product also contained gamma-linolenic acid and vitamin D₃, which were absent from the placebo, these effects cannot be attributed to omega-3 alone.
Overall, both treatment trials reported improvement in AD severity with omega-3 supplementation. However, both were small and short, and one used a multi-component product.
Narrative synthesis of findings
Across all included studies, the effects of omega-3 supplementation on AD differed according to clinical indication. In prevention trials, prenatal supplementation did not show a consistent benefit. Lower IgE-associated eczema was reported in two trials in high-risk families: one small trial (15) and one larger trial in which the effect was not significant after adjustment and did not persist at 3 and 6 years (13, 19, 20). One small trial found no difference in AD frequency but milder disease among affected infants (14), the two most recent trials found no overall effect (7, 12), and one trial reported more eczema with omega-3 (16).
None of the three postnatal prevention trials found a significant effect (10, 11, 17).
In treatment trials, both studies reported improvement in AD severity (8, 9). However, this evidence comes from two small, short trials. In one of them, SCORAD was not compared directly between groups, and the product also contained gamma-linolenic acid and vitamin D₃ (9).
Because all treatment trials were postnatal and most prevention trials were prenatal, differences between prenatal and postnatal findings largely reflect differences in clinical indication rather than timing alone. A direct comparison of timing was only possible within prevention trials, where neither approach showed a consistent effect.
The included trials used different formulations, but none directly compared EPA: and DHA-dominant supplements in children with AD. The only trial with both EPA-rich and DHA-rich arms reported more eczema in both groups than with placebo (16). Therefore, no conclusion can be drawn about the relative effectiveness of EPA and DHA.
Summary of findings
Overall, omega-3 supplementation did not consistently prevent AD when given prenatally or postnatally. Limited evidence from two small treatment trials suggests a possible benefit in children with established AD.
Strengths, limitations, and future directions
Discussion: Strengths, limitations, and future directions
A key strength of the current evidence base is its restriction to randomized controlled trials, which enhances internal validity and supports cautious causal interpretation. The search was updated, multiple reports from the same trial were combined at the trial level, and trials were grouped by clinical indication as well as timing. The emerging recognition that biological heterogeneity, including genetic variation, influences response to omega-3 supplementation represents an important advance (7).
Nevertheless, important limitations remain. The number of trials in each group was small, and trials differed in dose, formulation, timing, population and outcome definitions, which prevented meta-analysis. Many trials were conducted in relatively homogeneous populations, limiting generalizability across ethnic and geographic settings. Outcome assessment varied substantially, with several studies relying on parent-reported symptoms or treatment use rather than blinded clinician-assessed severity indices. Follow-up ranged from 4 weeks to 10 years, and both treatment trials were short, leaving uncertainty regarding the durability of observed benefits.
Two trials used multi-component interventions (9, 11) and two had factorial designs (11, 12), so effects cannot always be attributed to omega-3 alone. Three trials were judged at high risk of bias, all because of missing outcome data (12, 16, 17). An important limitation is that Embase was not searched, and Web of Science was not included in the updated search because our institution does not provide access, so some eligible trials may have been missed.
A formal certainty-of-evidence assessment (Grading of Recommendations Assessment, Development and Evaluation, GRADE) was not performed, given the small number of heterogeneous trials and the absence of meta-analysis.
Future research should prioritize adequately powered treatment trials in children with established AD, genotype-stratified randomized trials, direct comparisons between EPA: and DHA-dominant formulations, and longer follow-up periods. Greater standardization of outcome measures, such as SCORAD or the Eczema Area and Severity Index (EASI) assessed by blinded investigators, would further improve cross-study comparability. Addressing these gaps will be essential for refining clinical recommendations and clarifying the role of omega-3 fatty acids in both the prevention and management of childhood atopic dermatitis.
Source: Strengths, limitations, and future directions Source: Strengths, limitations, and future directions Source: Strengths, limitations, and future directionsClinical implications
This systematic review may inform clinical decision-making regarding omega-3 supplementation for the prevention and treatment of pediatric atopic dermatitis.
Current evidence suggests that omega-3 supplementation should not be considered a uniform intervention, as clinical effects may vary according to clinical indication, timing of exposure, fatty-acid composition, and biological context.
Randomized data do not support routine prenatal or postnatal omega-3 supplementation for the prevention of atopic dermatitis. In children with established disease, two small trials suggest a possible benefit, but the evidence is currently insufficient to recommend omega-3 supplementation as an adjunctive treatment outside research settings.
Before clinical recommendations can be made, larger trials are needed, ideally comparing formulations and considering individual risk factors, including genetic background.
Source: Clinical implications Source: Clinical implications Source: Clinical implications Source: Clinical implicationsResults
Study selection
The searches identified 614 records (PubMed, n = 292; Web of Science, n = 117; Google Scholar, n = 205), including the original search and the updated PubMed search. After removal of 192 duplicates, 422 records were screened by title and abstract, of which 395 were excluded. Of the 27 reports sought for retrieval, 6 could not be retrieved, and 21 were assessed for eligibility. Six reports were excluded, with reasons listed in Supplementary Table S2. In total, 11 randomized controlled trials, reported in 15 publications, were included (Figure 1).
Six trials were identified in the original search, and five additional trials were identified in the updated search.
Study characteristics
The included trials were published between 2003 and 2024 and varied widely in sample size (48 to 736 participants), intervention timing, omega-3 formulation, dosage, and duration of follow-up (4 weeks to 10 years). Study populations included pregnant women with or without a personal history of allergic disease, preterm and term infants at varying baseline risks for atopy, and pediatric patients with established atopic dermatitis. Omega-3 interventions consisted of EPA-rich, DHA-rich, and mixed LCPUFA formulations administered at various daily dosages, compared against controls including soy oil, olive oil, vegetable oil, omega-6-rich oils, medium-chain triglycerides, or paraffin; one trial compared high-DHA with standard-DHA feeds rather than placebo (10).
Two trials used multi-component interventions, combining omega-3 with gamma-linolenic acid and vitamin D₃ (9) or with omega-6 restriction (11), and two had factorial designs (11, 12). Atopic dermatitis outcomes were defined as physician-diagnosed eczema, IgE-associated eczema, parent-reported or nurse-assessed eczema, or SCORAD. Study characteristics are summarized in Table 1.
Quality assessment
Risk of bias was assessed using RoB 2 for the main AD outcome of each trial (Figure 2; Supplementary Table S4). Overall risk of bias was low for one trial (13), some concerns for seven trials (7Not reported11, 14, 15), and high for three trials (12, 16, 17). All three high-risk judgments were due to missing outcome data: 84 of 126 randomized women were included in one trial (16), 264 of 439 randomized participants contributed 24-month data in another (12), and 323 of 420 randomized infants were assessed at 12 months, with greater loss from the fish oil group, in the third (17).
Some concerns most often arose from missing outcome data and from the lack of an accessible prespecified analysis plan for the specific result. Outcome measurement raised concerns where eczema was based on parent or maternal report, or where blinding was not maintained throughout follow-up (7, 11, 12, 16). Two trials did not describe sequence generation and allocation concealment in sufficient detail (11, 15).
Characteristics of included randomized controlled trials evaluating omega-3 supplementation and atopic dermatitis.
| Study (Year) | Populations | N randomized/analysed | Intervention (Daily dose; Timing) | Comparator | AD outcome; follow-up | Main AD result (intervention vs. control; 95% CI) |
|---|---|---|---|---|---|---|
| Prevention: Prenatal Supplementation | ||||||
| Dunstan et al. (14) (2003) | Pregnant atopic women | 98/ 83a | 4 × 1 g fish oil capsules/day = 3.7 g n-3 PUFA/day (56.0% DHA, 27.7% EPA); 20 weeks' gestation to delivery | 4 × 1 g olive oil capsules/day | physician-diagnosed eczema responsive to topical steroids. Severity: modified SCORAD, (12 months) | AD: 18/40 vs. 13/43; OR 1.88 (0.77 to 4.65). Severe AD among infants with AD: 1/18 vs. 5/13; OR 0.09 (0.01 to 0.94) |
| Furuhjelm et al. (15, 18) (2009) | Pregnant women with family history of allergy | 145/117a | Nine 500 mg capsules/day (Bio Marin, Pharma Nord): 1.6 g EPA (35%) + 1.1 g DHA (25%) + 23 mg alpha-tocopherol per day; 25th gestational week to average 3-4 months of breastfeeding | nine soy oil capsules/day | IgE-associated eczema,(1 and 2 years) | 1 year: 4/52 vs. 15/63; adjusted OR 0.22 (0.06 to 0.81). 2 years (cumulative): 5/54 vs. 15/63; adjusted OR 0.33 (0.10 to 1.10) |
| Palmer et al. (13, 19, 20) (2012) | Infants at high hereditary risk: mother, father or sibling with medically diagnosed allergic disease | 706/706b | 3 × 500 mg DHA-rich fish oil concentrate capsules daily (800 mg DHA + 100 mg EPA; 900 mg n-3 LCPUFA/day); 21 weeks' gestation to delivery. | 3 × 500 mg vegetable oil capsules daily | IgE-associated eczema,(1,3,6 years) | 1 year: 26/368 vs. 39/338; unadjusted RR 0.61 (0.38 to 0.98); adjusted RR 0.64 (0.40 to 1.03). 3 years: 13.8% vs. 19.0%; adjusted RR 0.75 (0.53 to 1.05). 6 years (IgE-associated allergic disease): 31.5% vs. 31.5%; adjusted RR 1.04 (0.82 to 1.33) |
| Berman et al. (16) (2016) | Pregnant women with past depression | 126/ 84c | EPA-rich fish oil 1060 mg EPA + 274 mg DHA; DHA-rich fish oil 900 mg DHA + 180 mg EPA. Once daily; Started at 12-20 weeks' gestation | Soy oil | Mother-reported by phone, No clinical examination or allergy testing, (36 months) | EPA 13/31 and DHA 10/26 vs. placebo 3/27; adjusted OR 8.1 (1.4 to 46.3) for EPA and 9.5 (1.5 to 59.6) for DHA |
| Komulainen et al. (12) (2023) | Women with self-reported prepregnancy BMI ≥25 kg/m2, under 18 gestational weeks, without chronic disease (allergic disease allowed) | 439/264d | Fish oil 2 capsules/day = 2.4 g n-3 (1.9 g DHA, 0.22 g EPA; Croda); 14 ± 2 gestational weeks to 6 months postpartume | medium-chain fatty acids | Atopic eczema diagnosed by the child's personal physician, (12 and 24 months) | 24 months: 11/68 vs. 11/66e; fish oil main effect adjusted OR 1.22 (0.64 to 2.33) |
| Chen et al. (7) (2024) | Pregnant women not selected for allergy risk | 736/635 | 2.4 g/d of n-3 LCPUFA (55% EPA and 37% DHA) Once Daily; 24 weeks' gestation to 1 week postpartum | olive oil | Childhood AD diagnosis clinic by Hanifin and Rajka criteria, until age 10 years | No overall effect: HR 1.00 (0.76 to 1.33). Effect modified by maternal PTGS1 genotype (interaction P < 0.001)f |
| Prevention: Postnatal Supplementation | ||||||
| Marks et al. (11) (2006) | Pregnant women whose unborn child had an increased risk of asthma | 616/516 | 500mg of daily tuna fish oil (∼184 mg omega-3); started by bottle-feeding or solids by 6 months to 5 yearse,g | Sunola oil capsules | Current eczema inspection by the assessment nurse OR parent-reported itchy rash; 5 years | 54/267 vs. 59/249; RR 0.85 (0.61 to 1.17) |
| Gunaratne et al. (10) (2019) | Preterm infants <33 wk gestation | 657/569 | Breast-feeding mothers: six 0.5 g DHA-rich fish oil capsules/day (900 mg DHA + 195 mg EPA) to raise breast milk DHA to ∼1% of total fatty acids. Infants needing formula: high-DHA preterm formula (∼1.0% DHA, ∼0.6% AA). 2-4 d of postnatal age to 40 wk postmenstrual age | Standard-DHA feedsh | parent-reported via ISAAC questionnaire; 18 months and 7 years | Previous 12 months: 36/278 vs. 28/291; adjusted RR 1.38 (0.86 to 2.21). Birth to 7 years: 43/278 vs. 43/291; adjusted RR 1.08 (0.72 to 1.62) |
| D'Vaz et al. (17) (2012) | Healthy term infants of allergic women | 420/ 323 | Fish oil capsule 650 mg daily providing 280 mg DHA + 110 mg EPA; From Birth to 6 months of age | Olive oil capsule 650 mg daily | Physician-diagnosed eczema (Hanifin: Rajka criteria); 6 and 12 months | 61/156 vs. 68/167; no significant difference (effect estimate not reported) |
| Treatment | ||||||
| Mirrahimi et al. (8) (2023) | Children aged 3 months to 18 years with AD | 48/43a | PA softgels 250 mg twice daily (500 mg/day) for 4 weeks | Placebo softgels | SCORAD (online calculator) at baseline; 2 and 4 weeks | SCORAD at 4 weeks: 18.01 ± 10.63 vs. 30.11 ± 9.58 (P = 0.001)a. Topical corticosteroids needed: 7/21 vs. 14/22 (P = 0.047) |
| Niseteo et al. (9) (2024) | Children aged 1 to 8 years with AD and SCORAD >25 (moderate to severe) | 53/52 | 600 mg EPA + 400 mg DHA with GLA 10 mg and vitamin D₃ 5 mcg; 4 monthsg | 5 mL once daily: MCT oil | SCORAD, PO-SCORAD and TCS use; 4 months | Median SCORAD, within group: 42 to 25 (P < 0.001) vs. 39 to 39 (P = 0.795); no between-group SCORAD comparison. PO-SCORAD change: 13 vs. −1 (P < 0.001) |
Results are intervention vs. control. Doses are per day. Effect estimates are as reported by each trial.
Per-protocol analysis. bAll randomized infants analysed using multiple imputation. c126 women randomized in the original trial, 118 completed; 84 children analysed (secondary, unplanned analysis). dChildren analysed at 24 months. eFactorial design: Komulainen 2023 with probiotics (counts shown for fish oil + placebo vs. placebo + placebo; odds ratio is the fish oil main effect, interaction P = 0.593); Marks 2006 with house dust mite avoidance (diet groups shown). fPrespecified secondary analysis. gMulti-component intervention; effects cannot be attributed to omega-3 alone. hActive comparator, not placebo.
AA, arachidonic acid; AD, atopic dermatitis; BMI, body mass index; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; HR, hazard ratio; ISAAC, International Study of Asthma and Allergies in Childhood; LCPUFA, long-chain polyunsaturated fatty acids; MCT, medium-chain triglycerides; OR, odds ratio; PO-SCORAD, patient-oriented SCORAD; PUFA, polyunsaturated fatty acids; RR, relative risk; SCORAD, scoring atopic dermatitis; TCS, topical corticosteroids.
Conclusion
The evidence reviewed here indicates that the role of omega-3 fatty acids in atopic dermatitis is more nuanced than previously assumed. Prenatal supplementation, although biologically plausible, has produced mixed results, and one trial suggests that its effects may depend on maternal genetic differences that influence eicosanoid pathways. These findings may help explain why similar interventions have yielded conflicting outcomes and suggest that prenatal omega-3 intake is unlikely to function as a universal preventive measure.
Postnatal supplementation shows a similar picture for prevention. When omega-3 was given directly to infants, it did not reduce eczema in any of the three trials. In children with established atopic dermatitis, two small trials reported improvements in eczema severity and symptom burden, but these trials were short, and one used a multi-component product. EPA's interaction with arachidonic acid: derived mediators and its contribution to pro-resolving pathways offer a possible biological explanation, but differences between EPA and DHA have not been tested directly.
Taken together, the current literature supports a practical distinction between preventive and therapeutic applications. Omega-3 supplementation does not appear to prevent atopic dermatitis, although benefit in specific biologically defined subgroups cannot be excluded, while its possible role in treating established disease remains preliminary. Nevertheless, the field still faces important gaps. Sample sizes remain modest, outcome measures differ across trials, and long-term follow-up is often limited. Adequately powered treatment trials, greater attention to genetic stratification, clearer comparisons between EPA and DHA formulations, and standardized clinician-assessed outcomes would substantially strengthen future evidence.
Source: Conclusion Source: Conclusion Source: ConclusionAuthors’ abstract
Background
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease of childhood. Omega-3 fatty acids have been investigated for their potential role in modulating allergic inflammation; however, evidence regarding their effectiveness in preventing or treating AD remains inconsistent.
Objective
To systematically review and narratively synthesize randomized controlled trial evidence on prenatal and postnatal omega-3 fatty acid supplementation for the prevention and treatment of AD in infants and children.
Methods
PubMed and Web of Science were searched in October 2025, with an updated PubMed search in October 2026, to identify randomized controlled trials of omega-3 supplementation given during pregnancy or after birth that reported AD outcomes. Data were extracted, and risk of bias was assessed using RoB 2. Trials were grouped by clinical indication (prevention or treatment) and timing of supplementation, and a narrative synthesis was performed because of substantial heterogeneity.
Results
Eleven randomized controlled trials were included: nine prevention trials (six prenatal and three postnatal) and two treatment trials in children with established AD. Prenatal supplementation did not show a consistent preventive effect. Lower IgE-associated eczema was reported in two trials in high-risk families, but the effect was not always significant after adjustment and did not persist at longer follow-up; the two most recent trials found no overall effect, and one trial reported more eczema with omega-3. In one trial, the effect differed by maternal PTGS1 (COX-1) genotype.
None of the three postnatal prevention trials found a significant effect. Both treatment trials reported improvement in AD severity, but they were small and short, and one used a multi-component product. Risk of bias was low in one trial, raised some concerns in seven, and was high in three.
Conclusions
Randomized controlled trial evidence does not support omega-3 supplementation for the prevention of AD, whether given prenatally or postnatally. Limited evidence suggests a possible benefit in children with established AD, which should be tested in larger trials. Any role of fatty acid composition or maternal genotype remains hypothesis-generating.
Systematic Review Registration
PROSPERO CRD420251161453.
Read the full paper
Introduction
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease driven by skin barrier dysfunction and immune dysregulation that currently affects up to 20% of children globally (1, 2). Often serving as the primary clinical entry point for the “atopic march,” AD frequently precedes the development of asthma and allergic rhinitis, making early and effective intervention a public health priority (1).
While topical corticosteroids remain the gold standard for flare management, their long-term use is increasingly hampered by “steroid phobia” among caregivers, driving a critical demand for evidence-based, non-pharmacological adjuncts (3, 4).
The therapeutic potential of omega-3 polyunsaturated fatty acids (n-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has gained significant traction due to their role in resolving systemic inflammation. Mechanistically, these fatty acids compete with arachidonic acid for metabolic conversion by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. This shift reduces the production of proinflammatory series 2 prostaglandins and series 4 leukotrienes, while promoting the synthesis of specialized pro-resolving mediators (SPMs) such as resolvins and protectins (5).
Despite this biological plausibility, clinical results have historically remained inconsistent. Previous meta-analyses combining observational studies and randomized controlled trials have reported heterogeneous associations between prenatal omega-3 intake and allergic disease outcomes in offspring, underscoring the complexity of translating biological mechanisms into clinical benefit (6).
Recent evidence suggests that this variability may partly reflect differences in dosing, timing, and individual genetic background. A 2024 prespecified secondary analysis of the COPSAC2010 trial found no overall effect of prenatal fish oil on childhood AD, but the effect differed by maternal PTGS1 (COX-1) genotype, suggesting that a one-size-fits-all approach to nutritional intervention may be insufficient (7).
Furthermore, two recent triple-blind randomized trials in children with established AD, one using EPA alone and one using a combined EPA and DHA supplement, reported improvements in AD severity and topical corticosteroid use (8, 9).
To our knowledge, no systematic review has separated randomized trial evidence by both the timing of supplementation (prenatal or postnatal) and the clinical indication (prevention or treatment of established AD). This review therefore aims to synthesize randomized controlled trial evidence on omega-3 supplementation for AD, considering timing, indication, and formulation.
Methods
Study design
This study was conducted as a systematic review of randomized controlled trials (RCTs) evaluating the effects of prenatal and postnatal omega-3 (n-3 long-chain polyunsaturated fatty acid) supplementation for the prevention and treatment of atopic dermatitis (AD) and related allergic outcomes in children.
Reporting standards
This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The study selection process, including identification, screening, eligibility, and inclusion of studies, is presented in a PRISMA flow diagram (Figure 1).
PRISMA 2020 flow diagram of study selection.
Protocol registration
The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD420251161453). Although the protocol initially allowed inclusion of multiple study designs, only randomized controlled trials met the eligibility criteria following full-text screening.
Eligibility criteria
Types of studies
Only randomized controlled trials were included. Observational studies, animal studies, reviews, editorials, conference abstracts, and nonrandomized trials were excluded.
Types of participants
Eligible participants included pregnant women (prenatal supplementation trials) and pediatric populations (infants or children). Studies evaluating either prevention of atopic dermatitis or treatment of established atopic dermatitis were eligible.
Types of interventions
The intervention of interest was omega-3 fatty acid supplementation, including formulations containing docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or combined omega-3 preparations. Supplementation administered prenatally, postnatally, or both was eligible. Trials using multi-component supplements were eligible if omega-3 fatty acids were a main component; these were identified and interpreted separately, as effects could not be attributed to omega-3 alone.
Outcomes
Studies were included if they reported at least one atopic dermatitis outcome, including incidence or prevalence of AD (eczema), severity of AD assessed using validated tools (e.g., SCORAD), or use of topical corticosteroids. Other allergic outcomes were extracted where reported.
Information sources
A systematic literature search was conducted in October 2025 using the following electronic databases: PubMed and Web of Science. Additional records were identified through supplementary searching of Google Scholar and reference lists of included studies. The search was updated on 2 October 2026 in PubMed, as Web of Science and Embase were not accessible through our institution at the time of the update. Reference lists of included trials were also checked to identify additional eligible studies.
Search strategy
A structured search strategy was developed using relevant keywords and medical subject headings related to omega-3 fatty acids, atopic dermatitis, eczema, pregnancy, infants, and randomized controlled trials. All retrieved records were imported into Rayyan systematic review software for duplicate removal and screening. Records from the updated search were added to the same Rayyan project, and duplicates of previously screened records were removed. The full search strategy for the updated search is provided in Supplementary Table S1.
Study selection
Study selection was performed using Rayyan. Four reviewers independently screened studies in two stages: title and abstract screening, followed by full-text review for eligibility when necessary. Any disagreements regarding study inclusion were resolved through discussion or consultation with a senior reviewer. The same process was applied to records identified in the updated search. Reports excluded at eligibility assessment, with reasons, are listed in Supplementary Table S2.
Data extraction
Data were extracted using a predefined data extraction form. Extracted information included author and year of publication, study population, timing of omega-3 supplementation (prenatal or postnatal), clinical indication (prevention or treatment), omega-3 formulation, dosage and duration, comparator, outcomes assessed, event counts and effect estimates with 95% confidence intervals where available, and length of follow-up. Data were extracted by one reviewer and checked against the original reports by a second reviewer. When multiple publications reported results from the same trial, they were treated as a single study.
Data from all reports were extracted and organized at the trial level, including longer-term follow-up outcomes where available. A summary of study characteristics and outcomes is presented in Table 1, with the complete data extraction table provided in Supplementary Table S3.
Characteristics of included randomized controlled trials evaluating omega-3 supplementation and atopic dermatitis.
| Study (Year) | Populations | N randomized/analysed | Intervention (Daily dose; Timing) | Comparator | AD outcome; follow-up | Main AD result (intervention vs. control; 95% CI) |
|---|---|---|---|---|---|---|
| Prevention: Prenatal Supplementation | ||||||
| Dunstan et al. (14) (2003) | Pregnant atopic women | 98/ 83a | 4 × 1 g fish oil capsules/day = 3.7 g n-3 PUFA/day (56.0% DHA, 27.7% EPA); 20 weeks' gestation to delivery | 4 × 1 g olive oil capsules/day | physician-diagnosed eczema responsive to topical steroids. Severity: modified SCORAD, (12 months) | AD: 18/40 vs. 13/43; OR 1.88 (0.77 to 4.65). Severe AD among infants with AD: 1/18 vs. 5/13; OR 0.09 (0.01 to 0.94) |
| Furuhjelm et al. (15, 18) (2009) | Pregnant women with family history of allergy | 145/117a | Nine 500 mg capsules/day (Bio Marin, Pharma Nord): 1.6 g EPA (35%) + 1.1 g DHA (25%) + 23 mg alpha-tocopherol per day; 25th gestational week to average 3-4 months of breastfeeding | nine soy oil capsules/day | IgE-associated eczema,(1 and 2 years) | 1 year: 4/52 vs. 15/63; adjusted OR 0.22 (0.06 to 0.81). 2 years (cumulative): 5/54 vs. 15/63; adjusted OR 0.33 (0.10 to 1.10) |
| Palmer et al. (13, 19, 20) (2012) | Infants at high hereditary risk: mother, father or sibling with medically diagnosed allergic disease | 706/706b | 3 × 500 mg DHA-rich fish oil concentrate capsules daily (800 mg DHA + 100 mg EPA; 900 mg n-3 LCPUFA/day); 21 weeks' gestation to delivery. | 3 × 500 mg vegetable oil capsules daily | IgE-associated eczema,(1,3,6 years) | 1 year: 26/368 vs. 39/338; unadjusted RR 0.61 (0.38 to 0.98); adjusted RR 0.64 (0.40 to 1.03). 3 years: 13.8% vs. 19.0%; adjusted RR 0.75 (0.53 to 1.05). 6 years (IgE-associated allergic disease): 31.5% vs. 31.5%; adjusted RR 1.04 (0.82 to 1.33) |
| Berman et al. (16) (2016) | Pregnant women with past depression | 126/ 84c | EPA-rich fish oil 1060 mg EPA + 274 mg DHA; DHA-rich fish oil 900 mg DHA + 180 mg EPA. Once daily; Started at 12-20 weeks' gestation | Soy oil | Mother-reported by phone, No clinical examination or allergy testing, (36 months) | EPA 13/31 and DHA 10/26 vs. placebo 3/27; adjusted OR 8.1 (1.4 to 46.3) for EPA and 9.5 (1.5 to 59.6) for DHA |
| Komulainen et al. (12) (2023) | Women with self-reported prepregnancy BMI ≥25 kg/m2, under 18 gestational weeks, without chronic disease (allergic disease allowed) | 439/264d | Fish oil 2 capsules/day = 2.4 g n-3 (1.9 g DHA, 0.22 g EPA; Croda); 14 ± 2 gestational weeks to 6 months postpartume | medium-chain fatty acids | Atopic eczema diagnosed by the child's personal physician, (12 and 24 months) | 24 months: 11/68 vs. 11/66e; fish oil main effect adjusted OR 1.22 (0.64 to 2.33) |
| Chen et al. (7) (2024) | Pregnant women not selected for allergy risk | 736/635 | 2.4 g/d of n-3 LCPUFA (55% EPA and 37% DHA) Once Daily; 24 weeks' gestation to 1 week postpartum | olive oil | Childhood AD diagnosis clinic by Hanifin and Rajka criteria, until age 10 years | No overall effect: HR 1.00 (0.76 to 1.33). Effect modified by maternal PTGS1 genotype (interaction P < 0.001)f |
| Prevention: Postnatal Supplementation | ||||||
| Marks et al. (11) (2006) | Pregnant women whose unborn child had an increased risk of asthma | 616/516 | 500mg of daily tuna fish oil (∼184 mg omega-3); started by bottle-feeding or solids by 6 months to 5 yearse,g | Sunola oil capsules | Current eczema inspection by the assessment nurse OR parent-reported itchy rash; 5 years | 54/267 vs. 59/249; RR 0.85 (0.61 to 1.17) |
| Gunaratne et al. (10) (2019) | Preterm infants <33 wk gestation | 657/569 | Breast-feeding mothers: six 0.5 g DHA-rich fish oil capsules/day (900 mg DHA + 195 mg EPA) to raise breast milk DHA to ∼1% of total fatty acids. Infants needing formula: high-DHA preterm formula (∼1.0% DHA, ∼0.6% AA). 2-4 d of postnatal age to 40 wk postmenstrual age | Standard-DHA feedsh | parent-reported via ISAAC questionnaire; 18 months and 7 years | Previous 12 months: 36/278 vs. 28/291; adjusted RR 1.38 (0.86 to 2.21). Birth to 7 years: 43/278 vs. 43/291; adjusted RR 1.08 (0.72 to 1.62) |
| D'Vaz et al. (17) (2012) | Healthy term infants of allergic women | 420/ 323 | Fish oil capsule 650 mg daily providing 280 mg DHA + 110 mg EPA; From Birth to 6 months of age | Olive oil capsule 650 mg daily | Physician-diagnosed eczema (Hanifin: Rajka criteria); 6 and 12 months | 61/156 vs. 68/167; no significant difference (effect estimate not reported) |
| Treatment | ||||||
| Mirrahimi et al. (8) (2023) | Children aged 3 months to 18 years with AD | 48/43a | PA softgels 250 mg twice daily (500 mg/day) for 4 weeks | Placebo softgels | SCORAD (online calculator) at baseline; 2 and 4 weeks | SCORAD at 4 weeks: 18.01 ± 10.63 vs. 30.11 ± 9.58 (P = 0.001)a. Topical corticosteroids needed: 7/21 vs. 14/22 (P = 0.047) |
| Niseteo et al. (9) (2024) | Children aged 1 to 8 years with AD and SCORAD >25 (moderate to severe) | 53/52 | 600 mg EPA + 400 mg DHA with GLA 10 mg and vitamin D₃ 5 mcg; 4 monthsg | 5 mL once daily: MCT oil | SCORAD, PO-SCORAD and TCS use; 4 months | Median SCORAD, within group: 42 to 25 (P < 0.001) vs. 39 to 39 (P = 0.795); no between-group SCORAD comparison. PO-SCORAD change: 13 vs. −1 (P < 0.001) |
Results are intervention vs. control. Doses are per day. Effect estimates are as reported by each trial.
Per-protocol analysis. bAll randomized infants analysed using multiple imputation. c126 women randomized in the original trial, 118 completed; 84 children analysed (secondary, unplanned analysis). dChildren analysed at 24 months. eFactorial design: Komulainen 2023 with probiotics (counts shown for fish oil + placebo vs. placebo + placebo; odds ratio is the fish oil main effect, interaction P = 0.593); Marks 2006 with house dust mite avoidance (diet groups shown). fPrespecified secondary analysis. gMulti-component intervention; effects cannot be attributed to omega-3 alone. hActive comparator, not placebo.
AA, arachidonic acid; AD, atopic dermatitis; BMI, body mass index; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; HR, hazard ratio; ISAAC, International Study of Asthma and Allergies in Childhood; LCPUFA, long-chain polyunsaturated fatty acids; MCT, medium-chain triglycerides; OR, odds ratio; PO-SCORAD, patient-oriented SCORAD; PUFA, polyunsaturated fatty acids; RR, relative risk; SCORAD, scoring atopic dermatitis; TCS, topical corticosteroids.
Risk of bias assessment
The methodological quality of included studies was assessed using the Cochrane Risk of Bias tool version 2 (RoB 2). Five domains were evaluated: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of outcomes, and bias in selection of the reported result. Each domain was rated as low risk of bias, some concerns, or high risk of bias, and an overall risk of bias judgment was assigned in accordance with Cochrane guidance.
Risk of bias was assessed for the main AD outcome of each trial, and a justification was recorded for each domain (Supplementary Table S4). Results were summarized using a traffic-light plot (Figure 2).
Risk of bias assessment of included trials using the cochrane roB 2 tool. D1, randomization process; D2, deviations from intended interventions; D3, missing outcome data; D4, measurement of the outcome; D5, selection of the reported result. Green, low risk of bias; yellow, some concerns; red, high risk of bias. Overall risk of bias was low for one trial, some concerns for seven trials and high for three trials.
Data synthesis
Because included trials differed in clinical indication, studies were grouped first by indication (primary prevention of AD vs. treatment of established AD) and then by timing of supplementation (prenatal vs. postnatal). Direct comparison of prenatal and postnatal supplementation was considered only within the prevention category. A meta-analysis was not performed because trials differed substantially in supplementation dose and formulation, timing of initiation, definition of AD outcomes (e.g., any eczema vs. IgE-associated eczema), and length of follow-up. Instead, a structured narrative synthesis was conducted, considering methodological quality and risk of bias.
Trial-level effect estimates with 95% confidence intervals are reported in Table 1 where available.
Results
Study selection
The searches identified 614 records (PubMed, n = 292; Web of Science, n = 117; Google Scholar, n = 205), including the original search and the updated PubMed search. After removal of 192 duplicates, 422 records were screened by title and abstract, of which 395 were excluded. Of the 27 reports sought for retrieval, 6 could not be retrieved, and 21 were assessed for eligibility. Six reports were excluded, with reasons listed in Supplementary Table S2. In total, 11 randomized controlled trials, reported in 15 publications, were included (Figure 1).
Six trials were identified in the original search, and five additional trials were identified in the updated search.
Study characteristics
The included trials were published between 2003 and 2024 and varied widely in sample size (48 to 736 participants), intervention timing, omega-3 formulation, dosage, and duration of follow-up (4 weeks to 10 years). Study populations included pregnant women with or without a personal history of allergic disease, preterm and term infants at varying baseline risks for atopy, and pediatric patients with established atopic dermatitis. Omega-3 interventions consisted of EPA-rich, DHA-rich, and mixed LCPUFA formulations administered at various daily dosages, compared against controls including soy oil, olive oil, vegetable oil, omega-6-rich oils, medium-chain triglycerides, or paraffin; one trial compared high-DHA with standard-DHA feeds rather than placebo (10).
Two trials used multi-component interventions, combining omega-3 with gamma-linolenic acid and vitamin D₃ (9) or with omega-6 restriction (11), and two had factorial designs (11, 12). Atopic dermatitis outcomes were defined as physician-diagnosed eczema, IgE-associated eczema, parent-reported or nurse-assessed eczema, or SCORAD. Study characteristics are summarized in Table 1.
Quality assessment
Risk of bias was assessed using RoB 2 for the main AD outcome of each trial (Figure 2; Supplementary Table S4). Overall risk of bias was low for one trial (13), some concerns for seven trials (7Not reported11, 14, 15), and high for three trials (12, 16, 17). All three high-risk judgments were due to missing outcome data: 84 of 126 randomized women were included in one trial (16), 264 of 439 randomized participants contributed 24-month data in another (12), and 323 of 420 randomized infants were assessed at 12 months, with greater loss from the fish oil group, in the third (17).
Some concerns most often arose from missing outcome data and from the lack of an accessible prespecified analysis plan for the specific result. Outcome measurement raised concerns where eczema was based on parent or maternal report, or where blinding was not maintained throughout follow-up (7, 11, 12, 16). Two trials did not describe sequence generation and allocation concealment in sufficient detail (11, 15).
Results of individual studies
Prevention of atopic dermatitis
Nine trials evaluated omega-3 supplementation for the primary prevention of AD: six prenatal (7, 12Not reported16) and three postnatal (10, 11, 17).
Prenatal supplementation
Dunstan et al. (2003) conducted a randomized controlled trial involving 98 atopic pregnant women (14). Participants received fish oil providing 3.7 g n-3 PUFA daily (56% DHA, 27.7% EPA) or olive oil from 20 weeks' gestation until delivery, and 83 infants were analyzed per protocol. The frequency of AD at 12 months did not differ between groups (18/40 vs. 13/43; OR 1.88, 95% CI 0.77 to 4.65). However, among infants who developed AD, severe disease was less common in the fish oil group (1/18 vs. 5/13; OR 0.09, 95% CI 0.01 to 0.94), although this subgroup was small.
Furuhjelm et al. (2009) conducted a randomized controlled trial involving 145 pregnant women with a family history of allergy (15). Participants received 1.6 g EPA and 1.1 g DHA daily or soy oil from 25 weeks' gestation through an average of 3 to 4 months of breastfeeding. In the per-protocol analysis of 117 children, IgE-associated eczema at 1 year was lower in the omega-3 group (4/52, 8% vs. 15/63, 24%; adjusted OR 0.22, 95% CI 0.06 to 0.81). At 2 years, the cumulative incidence of IgE-associated eczema remained lower but was no longer significant after adjustment (adjusted OR 0.33, 95% CI 0.10 to 1.10), and any eczema did not differ between groups (18).
Twenty-five women who did not complete supplementation were excluded from the main analysis, more of them in the omega-3 group, and the intention-to-treat analysis showed only a trend.
Palmer et al. (2012) conducted a randomized controlled trial involving 706 infants at high hereditary risk within the DOMInO trial (13). Mothers received 900 mg n-3 LCPUFA daily (800 mg DHA and 100 mg EPA) or vegetable oil from 21 weeks' gestation until delivery. The primary outcome, IgE-associated allergic disease at 1 year, was not reduced (adjusted RR 0.70, 95% CI 0.45 to 1.09). IgE-associated eczema was less frequent in the omega-3 group (26/368, 7% vs. 39/338, 12%; unadjusted RR 0.61, 95% CI 0.38 to 0.98), but this was not significant after adjustment (adjusted RR 0.64, 95% CI 0.40 to 1.03).
At 3 years, IgE-associated eczema remained lower but not significantly (13.8% vs. 19.0%; adjusted RR 0.75, 95% CI 0.53 to 1.05) (19). At 6 years, IgE-associated allergic disease did not differ between groups (31.5% vs. 31.5%; adjusted RR 1.04, 95% CI 0.82 to 1.33) (20).
Berman et al. (2016) reported a secondary, unplanned analysis of a randomized controlled trial in pregnant women at risk of depression (16). Participants received EPA-rich fish oil (1060 mg EPA and 274 mg DHA), DHA-rich fish oil (900 mg DHA and 180 mg EPA) or soy oil from 12 to 20 weeks' gestation. In 84 of 118 completers, mother-reported eczema at 36 months was more frequent in both omega-3 groups than with placebo (EPA 13/31, 41.9%; DHA 10/26, 38.5%; placebo 3/27, 11.1%).
The adjusted odds ratios were 8.1 (95% CI 1.4 to 46.3) for EPA and 9.5 (95% CI 1.5 to 59.6) for DHA.
Komulainen et al. (2023) conducted a factorial randomized controlled trial involving 439 overweight pregnant women (12). Participants received fish oil (1.9 g DHA and 0.22 g EPA daily) and/or probiotics, or placebo, from about 14 weeks' gestation until 6 months postpartum. Fish oil had no effect on physician-diagnosed atopic eczema at 12 or 24 months. At 24 months, atopic eczema occurred in 11/68 (16%) children in the fish oil plus placebo group and 11/66 (17%) in the placebo-only group.
Chen et al. (2024) reported a prespecified secondary analysis of the COPSAC2010 trial, which included 736 pregnant women from an unselected cohort (7). Participants received 2.4 g n-3 LCPUFA daily (55% EPA and 37% DHA) or olive oil from 24 weeks' gestation until 1 week postpartum. There was no overall effect on AD up to 10 years of age (HR 1.00, 95% CI 0.76 to 1.33). However, the effect differed by maternal PTGS1 (COX-1) genotype (interaction P < 0.001). AD risk was lower among offspring of mothers with the TT genotype, unchanged with CT, and higher with CC.
Overall, prenatal omega-3 supplementation did not show a consistent preventive effect on AD. Reductions were mainly seen for IgE-associated eczema in high-risk families, were not always significant after adjustment, and did not persist at longer follow-up.
Postnatal supplementation
Marks et al. (2006) conducted a factorial randomized controlled trial involving 616 infants at high risk of asthma, which also tested house dust mite avoidance (11). The active diet group received tuna oil capsules with canola-based oils and spreads, and the control group received omega-6-rich oils and spreads with Sunola oil capsules, from the start of bottle-feeding or 6 months of age until 5 years. Among 516 children assessed at 5 years, current eczema did not differ between the active and control diet groups (54/267 vs. 59/249; RR 0.85, 95% CI 0.61 to 1.17).
Because the active diet also restricted omega-6 fatty acids, this effect cannot be attributed to omega-3 alone.
The DINO trial randomized 657 infants born before 33 weeks' gestation to high-DHA (about 1% of total fatty acids) or standard-DHA (about 0.3%) enteral feeds (10). The feeds were given through maternal fish oil capsules or preterm formula, from 2 to 4 days of age until 40 weeks' postmenstrual age. At 7 years, data were available for 569 children (87%). Parent-reported eczema in the previous 12 months did not differ between groups (13.0% vs. 9.6%; adjusted RR 1.38, 95% CI 0.86 to 2.21), and neither did eczema from birth to 7 years (15.5% vs. 14.8%; adjusted RR 1.08, 95% CI 0.72 to 1.62).
D'Vaz et al. (2012) conducted a randomized controlled trial involving 420 high-risk infants (17). Infants received fish oil (280 mg DHA and 110 mg EPA daily) or olive oil placebo from birth to 6 months, with clinical follow-up at 12 months (n = 323). This study found no significant difference in physician-diagnosed eczema between groups (61/156, 39.1% vs. 68/167, 40.7%), or in any other allergic outcome. Higher infant n-3 PUFA levels at 6 months were associated with lower eczema risk, but this association was not significant after correction for multiple comparisons or adjustment for group allocation.
Withdrawal was higher in the fish oil group (18.3% vs. 10.9%), and most fish oil participants correctly guessed their allocation.
Overall, none of the three postnatal prevention trials found a significant effect on AD.
Treatment of established atopic dermatitis
Two trials evaluated omega-3 supplementation in children with established AD, both postnatal by design (8, 9).
Mirrahimi et al. (2023) conducted a triple-blind randomized controlled trial involving 48 children aged 3 months to 18 years with AD (8). Participants received EPA 250 mg twice daily (500 mg/day) or placebo for 4 weeks, and both groups also used an emollient and 1% hydrocortisone ointment. Baseline SCORAD was similar between groups (49.65 ± 8.29 vs. 46.91 ± 11.37). SCORAD was lower in the EPA group at 2 weeks (30.50 ± 8.92 vs. 38.34 ± 10.52, P = 0.005) and at 4 weeks in the per-protocol analysis (18.01 ± 10.63 vs. 30.11 ± 9.58, P = 0.001).
Fewer children in the EPA group needed topical corticosteroids at 4 weeks (7/21, 33.3% vs. 14/22, 63.6%, P = 0.047). Confidence intervals were not reported.
Niseteo et al. (2024) conducted a triple-blind randomized controlled trial involving 53 children aged 1 to 8 years with moderate-to-severe AD (9). Participants received a daily syrup providing 600 mg EPA and 400 mg DHA, together with gamma-linolenic acid (10 mg) and vitamin D₃ (5 mcg), or placebo for 4 months, and 52 children were analyzed. Both groups also used emollients and low-potency topical corticosteroids. Median SCORAD decreased from 42 to 25 in the intervention group (P < 0.001) and did not change in the placebo group (39 to 39, P = 0.795), but SCORAD was not compared directly between groups.
Between-group comparisons showed greater improvement with the intervention in patient-oriented SCORAD (median change 13 vs. −1, P < 0.001), itch (3 vs. 0, P < 0.001), sleep disturbance (3 vs. 0, P = 0.001) and family quality of life (5 vs. 0, P < 0.001). Parent-reported topical corticosteroid use fell from 30 to 10 mg/month in the intervention group (P < 0.001) and rose from 30 to 50 mg/month in the placebo group (P = 0.031). Because the active product also contained gamma-linolenic acid and vitamin D₃, which were absent from the placebo, these effects cannot be attributed to omega-3 alone.
Overall, both treatment trials reported improvement in AD severity with omega-3 supplementation. However, both were small and short, and one used a multi-component product.
Narrative synthesis of findings
Across all included studies, the effects of omega-3 supplementation on AD differed according to clinical indication. In prevention trials, prenatal supplementation did not show a consistent benefit. Lower IgE-associated eczema was reported in two trials in high-risk families: one small trial (15) and one larger trial in which the effect was not significant after adjustment and did not persist at 3 and 6 years (13, 19, 20). One small trial found no difference in AD frequency but milder disease among affected infants (14), the two most recent trials found no overall effect (7, 12), and one trial reported more eczema with omega-3 (16).
None of the three postnatal prevention trials found a significant effect (10, 11, 17).
In treatment trials, both studies reported improvement in AD severity (8, 9). However, this evidence comes from two small, short trials. In one of them, SCORAD was not compared directly between groups, and the product also contained gamma-linolenic acid and vitamin D₃ (9).
Because all treatment trials were postnatal and most prevention trials were prenatal, differences between prenatal and postnatal findings largely reflect differences in clinical indication rather than timing alone. A direct comparison of timing was only possible within prevention trials, where neither approach showed a consistent effect.
The included trials used different formulations, but none directly compared EPA: and DHA-dominant supplements in children with AD. The only trial with both EPA-rich and DHA-rich arms reported more eczema in both groups than with placebo (16). Therefore, no conclusion can be drawn about the relative effectiveness of EPA and DHA.
Summary of findings
Overall, omega-3 supplementation did not consistently prevent AD when given prenatally or postnatally. Limited evidence from two small treatment trials suggests a possible benefit in children with established AD.
Discussion
Omega-3 polyunsaturated fatty acids (PUFAs) have long been proposed as potential modulators of atopic dermatitis (AD); however, clinical findings have remained inconsistent. This systematic review synthesizes evidence exclusively from randomized controlled trials, strengthening causal inference while necessarily limiting inclusion to relatively short-term, protocol-driven interventions. Across 11 trials, omega-3 supplementation did not consistently prevent AD, whether given during pregnancy or after birth, while two small trials in children with established AD reported improvements in disease severity. The findings highlight several factors that appear to drive heterogeneity across studies, particularly the clinical indication (prevention or treatment), the timing of supplementation, the specific omega-3 formulation used, and individual biological context.
Omega-3 fatty acids and atopic dermatitis: indication, timing, and biological context
Evidence from randomized controlled trials indicates that the effects of omega-3 supplementation on AD differ according to the clinical indication and the timing of exposure. Trials examining prenatal supplementation during pregnancy have reported mixed findings, including modest protective effects in some studies, no measurable benefit in others, and occasional increases in childhood eczema risk (7, 12Not reported16).
Trials giving omega-3 directly to infants to prevent AD found no significant effect (10, 11, 17). Benefit was reported only in trials treating children with established AD (8, 9). Because these trials address a different clinical question, they cannot show that postnatal supplementation is more effective than prenatal supplementation.
Prenatal supplementation: variability and genetic modifiers
The lack of consistency observed across prenatal trials suggests that omega-3 supplementation during pregnancy does not confer uniform protection against atopic dermatitis. The clearest benefits came from small trials in high-risk families. Lower IgE-associated eczema was reported in one trial when supplementation continued through breastfeeding (15), and one small trial found milder disease among affected infants, although not fewer cases (14). In the larger DOMInO trial, IgE-associated eczema was lower at 1 year but not significant after adjustment, and the effect did not persist at 3 and 6 years (13, 19, 20).
The two most recent trials found no overall effect (7, 12), and one trial reported more eczema with omega-3, although this was an unplanned secondary analysis based on maternal report (16). This variability may reflect the complexity of fetal immune development, which occurs within narrow developmental windows and is sensitive to timing, formulation, and maternal metabolic factors. It may also reflect chance or small-study effects, as well as differences between trials in population risk, supplementation during lactation, and outcome definitions (IgE-associated eczema versus any eczema).
Genetic factors may further modify response to prenatal omega-3 supplementation. In a prespecified secondary analysis of the COPSAC2010 trial, there was no overall effect of fish oil on childhood AD, but the effect differed by maternal PTGS1 (COX-1) genotype: risk was lower among offspring of mothers with the TT genotype, unchanged with CT, and higher with CC (7). Because this finding comes from a single trial and the CC subgroup was small, it should be interpreted as hypothesis-generating and needs independent replication.
Nevertheless, given the central role of COX-1 in eicosanoid synthesis, maternal genetic variation may partly explain the heterogeneity observed across prenatal trials. Taken together, the available evidence does not support routine universal prenatal omega-3 supplementation for AD prevention and suggests that any benefit may be confined to specific biologically defined subgroups.
Postnatal supplementation for prevention
Giving omega-3 directly to infants did not prevent AD in any of the three trials. In high-risk term infants, fish oil from birth to 6 months did not change eczema at 12 months (17). In preterm infants, high-DHA feeds did not change eczema up to 7 years compared with standard-DHA feeds (10), and in children at risk of asthma, an omega-3 and low omega-6 diet from infancy did not reduce eczema at 5 years (11).
These trials differed in population and design: one had higher dropout in the fish oil group and most parents correctly guessed their allocation (17), one compared two DHA doses rather than omega-3 with placebo (10), and one combined omega-3 with omega-6 restriction (11).
Treatment of established AD
In children with established AD, two small trials reported improvements with omega-3 supplementation. One found lower SCORAD scores with EPA alone after 2 and 4 weeks and fewer children needing topical corticosteroids at 4 weeks (8). The other reported greater improvements in patient-oriented SCORAD, itch, sleep disturbance and family quality of life with a combined supplement, although SCORAD itself was not compared directly between groups (9). However, both trials were small and short, and the product in the second trial also contained gamma-linolenic acid and vitamin D₃, so its effects cannot be attributed to omega-3 alone.
These findings should be considered preliminary. The relatively short time to improvement is consistent with a direct anti-inflammatory effect rather than long-term immune reprogramming, but this remains a hypothesis.
EPA and DHA: possible biological differences
Although EPA and DHA are commonly grouped together as omega-3 fatty acids, increasing evidence suggests that they exert distinct biological effects. EPA more directly competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, resulting in reduced production of proinflammatory eicosanoids and increased formation of E-series resolvins that promote resolution of inflammation and support epidermal barrier repair (5, 21). This provides a possible biological rationale for EPA-focused treatment, but it has not been tested in direct comparative trials.
No included trial compared EPA: and DHA-dominant supplements in children with AD, and the only trial with both EPA-rich and DHA-rich arms reported more eczema in both groups than with placebo (16).
DHA, by contrast, plays a prominent role in membrane structure, neurodevelopment, and early immune maturation. Its role in established AD is unclear, and evidence in this area largely comes from adult studies (22). Whether EPA: or DHA-dominant formulations differ in clinical effect remains a hypothesis that requires direct comparison in adequately powered pediatric trials.
Prevention and treatment as separate questions
Prevention and treatment trials answer different questions and should be interpreted separately. For prevention, neither prenatal nor postnatal supplementation showed a consistent effect, and any benefit may be limited to specific subgroups (7).
For treatment, early evidence suggests a possible benefit in children with established AD, but this is based on two small, short trials (8, 9). The current evidence therefore does not allow a conclusion that one timing of supplementation is better than the other.
Strengths, limitations, and future directions
A key strength of the current evidence base is its restriction to randomized controlled trials, which enhances internal validity and supports cautious causal interpretation. The search was updated, multiple reports from the same trial were combined at the trial level, and trials were grouped by clinical indication as well as timing. The emerging recognition that biological heterogeneity, including genetic variation, influences response to omega-3 supplementation represents an important advance (7).
Nevertheless, important limitations remain. The number of trials in each group was small, and trials differed in dose, formulation, timing, population and outcome definitions, which prevented meta-analysis. Many trials were conducted in relatively homogeneous populations, limiting generalizability across ethnic and geographic settings. Outcome assessment varied substantially, with several studies relying on parent-reported symptoms or treatment use rather than blinded clinician-assessed severity indices. Follow-up ranged from 4 weeks to 10 years, and both treatment trials were short, leaving uncertainty regarding the durability of observed benefits.
Two trials used multi-component interventions (9, 11) and two had factorial designs (11, 12), so effects cannot always be attributed to omega-3 alone. Three trials were judged at high risk of bias, all because of missing outcome data (12, 16, 17). An important limitation is that Embase was not searched, and Web of Science was not included in the updated search because our institution does not provide access, so some eligible trials may have been missed.
A formal certainty-of-evidence assessment (Grading of Recommendations Assessment, Development and Evaluation, GRADE) was not performed, given the small number of heterogeneous trials and the absence of meta-analysis.
Future research should prioritize adequately powered treatment trials in children with established AD, genotype-stratified randomized trials, direct comparisons between EPA: and DHA-dominant formulations, and longer follow-up periods. Greater standardization of outcome measures, such as SCORAD or the Eczema Area and Severity Index (EASI) assessed by blinded investigators, would further improve cross-study comparability. Addressing these gaps will be essential for refining clinical recommendations and clarifying the role of omega-3 fatty acids in both the prevention and management of childhood atopic dermatitis.
Clinical implications
This systematic review may inform clinical decision-making regarding omega-3 supplementation for the prevention and treatment of pediatric atopic dermatitis.
Current evidence suggests that omega-3 supplementation should not be considered a uniform intervention, as clinical effects may vary according to clinical indication, timing of exposure, fatty-acid composition, and biological context.
Randomized data do not support routine prenatal or postnatal omega-3 supplementation for the prevention of atopic dermatitis. In children with established disease, two small trials suggest a possible benefit, but the evidence is currently insufficient to recommend omega-3 supplementation as an adjunctive treatment outside research settings.
Before clinical recommendations can be made, larger trials are needed, ideally comparing formulations and considering individual risk factors, including genetic background.
Conclusion
The evidence reviewed here indicates that the role of omega-3 fatty acids in atopic dermatitis is more nuanced than previously assumed. Prenatal supplementation, although biologically plausible, has produced mixed results, and one trial suggests that its effects may depend on maternal genetic differences that influence eicosanoid pathways. These findings may help explain why similar interventions have yielded conflicting outcomes and suggest that prenatal omega-3 intake is unlikely to function as a universal preventive measure.
Postnatal supplementation shows a similar picture for prevention. When omega-3 was given directly to infants, it did not reduce eczema in any of the three trials. In children with established atopic dermatitis, two small trials reported improvements in eczema severity and symptom burden, but these trials were short, and one used a multi-component product. EPA's interaction with arachidonic acid: derived mediators and its contribution to pro-resolving pathways offer a possible biological explanation, but differences between EPA and DHA have not been tested directly.
Taken together, the current literature supports a practical distinction between preventive and therapeutic applications. Omega-3 supplementation does not appear to prevent atopic dermatitis, although benefit in specific biologically defined subgroups cannot be excluded, while its possible role in treating established disease remains preliminary. Nevertheless, the field still faces important gaps. Sample sizes remain modest, outcome measures differ across trials, and long-term follow-up is often limited. Adequately powered treatment trials, greater attention to genetic stratification, clearer comparisons between EPA and DHA formulations, and standardized clinician-assessed outcomes would substantially strengthen future evidence.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Author contributions
LA: Writing: review & editing, Conceptualization, Writing: original draft, Methodology. HA: Writing: review & editing, Investigation, Data curation, Visualization. FOS: Methodology, Validation, Writing: review & editing. FFS: Writing: original draft, Writing: review & editing. AA: Formal analysis, Writing: review & editing, Writing: original draft. NN: Supervision, Writing: review & editing.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/falgy.2026.1963461/full#supplementary-material
References
Edited by: Atsushi Fukunaga, Osaka Medical and Pharmaceutical University, Japan
Reviewed by: Hsuan-Hsiang Chen, National Taiwan University Hospital, Taiwan
Liang Chen, Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), Denmark
Publication and source details
Original title: Prenatal and postnatal omega-3 supplementation for the prevention and treatment of atopic dermatitis: a systematic review of randomized controlled trials
Leen M. Aljabri; Hams D. Alzahrani; Fatimah O. Sulaymani; Futun F. Sulaimani; Amal A. Alzahrani; Norah G. Nahhas
Frontiers in Allergy · 2026
* Correspondence: Leen M. Aljabri leenaljabriii@gmail.com © 2026 Aljabri, Alzahrani, Sulaymani, Sulaimani, Alzahrani and Nahhas. 2026Aljabri, Alzahrani, Sulaymani, Sulaimani, Alzahrani and Nahhashttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. The author(s) declared that financial support was not received for this work and/or its publication.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T10:23:37.717238+00:00
DOI: 10.3389/falgy.2026.1963461 ·